Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

BACKGROUND: Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether a single dose of lutetium-177 [(177)Lu]-prostate-specific membrane antigen (PSMA)-617 ((77)Lu-PSMA-617) followed by maintenance p...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Rahul, Starzinski, Stephanie, de Kouchkovsky, Ivan, Koshkin, Vadim, Bose, Rohit, Chou, Jonathan, Desai, Arpita, Kwon, Daniel, Kaushal, Samuel, Trihy, Lauren, Rastogi, Medini, Ippisch, Robin, Aslam, Maya, Friedlander, Terence, Feng, Felix, Oh, David, Cheung, Alexander, Small, Eric, Evans, Michael, Fong, Lawrence, Hope, Thomas A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667020/
https://www.ncbi.nlm.nih.gov/pubmed/37922930
http://dx.doi.org/10.1016/S1470-2045(23)00451-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667020/
https://www.ncbi.nlm.nih.gov/pubmed/37922930
http://dx.doi.org/10.1016/S1470-2045(23)00451-5

Ejemplares similares